Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | CFD | P00746 | 17/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trimazosin SCHEMBL122583 | 0.99 | HTR1A (0.98) | HTR1AADRA2CADRA1AKCNH2CFD | |
| Trimazosin SCHEMBL10363255 | 0.98 | HTR1A (0.96) | HTR1AADRA2CADRA1AKCNH2CFD | |
| Trimazosin SCHEMBL1650275 | 0.97 | HTR1A (0.95) | HTR1AADRA2CADRA1AKCNH2CFD | |
| SCHEMBL10952832 | 0.91 | HTR1A (0.83) | HTR1AADRA2CADRA1AKCNH2CFD | |
| Hydrochloric Acid SCHEMBL10957694 | 0.90 | HTR1A (0.81) | HTR1AADRA2CADRA1AKCNH2CFD | |
| SCHEMBL11814278 | 0.89 | HTR1A (0.80) | HTR1AADRA2CADRA1AKCNH2CFD | |
| SCHEMBL10951375 | 0.89 | ADRA1A (0.80) | HTR1AADRA2CADRA1AKCNH2CFD | |
| SCHEMBL10986215 | 0.85 | ADRA1A (0.75) | HTR1AADRA2CADRA1AKCNH2 | |
| SCHEMBL11813620 | 0.85 | HTR1A (0.74) | HTR1AADRA2CADRA1AKCNH2CFD | |
| SCHEMBL10957239 | 0.83 | HTR1A (0.70) | HTR1AADRA2CADRA1AKCNH2CFD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 4095 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4727545-A2 | COMBINATION TREATMENTS FOR DEPRESSION AND OTHER DISORDERS | Neurawell Therapeutics (US) | 2026-04-22 | — | — | EP | claimed |
| US-20250222008-A1 | EYEDROPS CONTAINING AN ALPHA1-BLOCKER FOR INHIBITING MYOPIA PROGRESSION | TSUBOTA LABORATORY, INC. (JP) | 2025-07-10 | — | — | US | claimed |
| US-20250213647-A1 | CHEMOKINE RECEPTORS AND ALPHA1 ADRENERGIC RECEPTORS/VASOPRESSIN RECEPTORS 1A HETEROMERS AS DRUG TARGETS FOR DISEASE | UNIVERSITY OF SOUTH FLORIDA | 2025-07-03 | — | — | US | claimed |
| US-20250186415-A1 | EXTENDED-RELEASE PHARMACEUTICAL COMPOSITIONS FOR TREATING EYE CONDITIONS | FIFTH THIRD BANK, NATIONAL ASSOCIATION, AS AGENT | 2025-06-12 | — | — | US | claimed |
| EP-4489858-A1 | EXTENDED-RELEASE PHARMACEUTICAL COMPOSITIONS FOR TREATING EYE CONDITIONS | Harrow IP, LLC (US) | 2025-01-15 | — | — | EP | claimed |
| WO-2024259412-A2 | COMBINATION TREATMENTS FOR DEPRESSION AND OTHER DISORDERS | Neurawell Therapeutics (US) | 2024-12-19 | — | — | WO | claimed |
| US-20240216375-A1 | USE OF SYMPATHETIC ACTIVATION INHIBITOR AND/OR ALPHA 1-ADRENERGIC RECEPTOR INHIBITOR IN PREPARING MEDICINE FOR TREATING DRY EYES | EYE INSTITUTE OF SHANDONG FIRST MEDICAL UNIVERSITY (CN) | 2024-07-04 | — | — | US | claimed |
| WO-2023192319-A1 | CHEMOKINE RECEPTORS AND ALPHA1 ADRENERGIC RECEPTORS/VASOPRESSIN RECEPTORS 1A HETEROMERS AS DRUG TARGETS FOR DISEASE | UNIVERSITY OF SOUTH FLORIDA (US) | 2023-10-05 | — | — | WO | claimed |
| WO-2023183932-A2 | MONOBODIES BINDING TO INTERCELLULAR ADHESION MOLECULE 2 (ICAM-2) | NEW YORK UNIVERSITY (US) | 2023-09-28 | — | — | WO | claimed |
| WO-2023172240-A1 | EXTENDED-RELEASE PHARMACEUTICAL COMPOSITIONS FOR TREATING EYE CONDITIONS | HARROW IP, LLC (US) | 2023-09-14 | — | — | WO | claimed |
| EP-0178122-A2 | Improved piroxicam-containing antiinflammatory compositions | PFIZER INC. (US) | 1986-04-16 | — | — | EP | claimed |
| EP-0178124-A1 | Improved antiinflammatory salts of piroxicam | PFIZER INC. (US) | 1986-04-16 | — | — | EP | claimed |
| US-4582832-A | Trimazosin as an anti-atherosclerosis agent | PFIZER INC. (US) | 1986-04-15 | — | — | US | claimed |
| US-4567179-A | Antiinflammatory salts of piroxicam | PFIZER, INC. (US) | 1986-01-28 | — | — | US | claimed |
| US-4550164-A | HYPOTENSIVE AGENTS; REACTING ISOBUTYLENE CARBONATE WITH SUBSTITUTED PIPERAZINE | PFIZER INC. (US) | 1985-10-29 | — | — | US | claimed |
| US-4532135-A | Treating renal damage by administering vasodilator having postsynaptic alpha-adrenoceptor blocking activity and antihyperlipidemic characteristics | EDWARDS K DAVID G | 1985-07-30 | — | — | US | claimed |
| EP-0060081-B1 | PIPERAZINOQUINAZOLINE ANTIHYPERTENSIVES, PROCESSES FOR PREPARING THEM, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND IMMUNOGENIC PROTEIN CONJUGATES FORMED FROM THEM | PFIZER INC. (US) | 1985-07-17 | — | — | EP | claimed |
| EP-0103387-A2 | Long-acting matrix tablet formulations | PFIZER INC. (US) | 1984-03-21 | — | — | EP | claimed |
| EP-0060081-A2 | Piperazinoquinazoline antihypertensives, processes for preparing them, pharmaceutical compositions containing them, and immunogenic protein conjugates formed from them | PFIZER INC. (US) | 1982-09-15 | — | — | EP | claimed |
| US-4130647-A | PRAZOSIN OR TRIMAZOSIN OR SALTS | PFIZER INC. (US) | 1978-12-19 | — | — | US | claimed |